• Loading stock data…

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Last Updated on August 2, 2022 by GlobeNewsWire

WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ will present at the following upcoming conferences:

BTIG Biotechnology Conference

Forum: Panel Date: Tuesday, August 9, 2022Time: 10:00 a.m. ET

H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Forum: Corporate Presentation / PanelDate: Wednesday, August 17, 2022 Time: 7:00 a.m. ET / 11:00 a.m. ET

A webcast and subsequent archived replay of the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference corporate presentation and panel may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. The live webcast of the BTIG panel will be available on BTIG’s conference website at the time of the event, and a replay will be available through BTIG’s research access.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert(R) technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA approved products, including YUTIQ(R) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina TartagliaStern IRDirect: 212-698-8700christina.tartaglia@sternir.com

Media Contact

Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: